The Residual Risk Reduction initiative (R3i) is a worldwide, academic, multidisciplinary, non-profit, Swiss-law Foundation established by international researchers and clinicians who recognize the importance of the high risk of fatal and non-fatal macro- and micro-vascular complications occurring in patients with atherogenic dyslipidemia who are already receiving the current standards of care.
 
To address this issue, it engages healthcare professionals in an innovative global initiative of academic research, education and advocacy with the goal of significantly improving and extending the lives of millions of patients with heart disease and/or diabetes.
 

To substantially extend and improve the lives of patients with heart disease and/or diabetes who have atherogenic dyslipidemia and remain at significantly increased risk of vascular diseases including heart attacks, impaired kidney function, loss of sight and limb amputation despite receiving current standards of care.
 

The objectives and programs of the R3i are defined in a manifesto published as a position paper in Diabetes and Vascular Disease Research (executive statement) and a supplement to The American Journal of Cardiology (full statement).^1,2
 

•  Research  to quantify the full extent of Residual Vascular Risk in patients with atherogenic dyslipidemia (cholesterol abnormalities increasing vascular risk) and to identify new targets for interventions.
  • - REALIST (REsiduAl risk, Lipids and Standard Therapies): 1st worldwide epidemiological survey to establish the link between TG/HDL-C and risk of CVD events (MACROvascular epidemiological survey) and microvascular complications of type 2 diabetes (MICROvascular epidemiological survey)
  • - Independent research grants related to Residual Vascular Risk
  
  
•  Educational programs  to create awareness of Residual Vascular Risk and encourage healthcare professionals, particularly Primary Care Physicians (PCPs), to translate the results of research into improved treatment strategies
  • - Global education programs
  • - CME accredited interactive program: R3 clinic
  • - R3i website
  • - Webinars (live web conferences)
  
  
•  Advocacy  to ensure that the issue of Residual Vascular Risk associated with atherogenic dyslipidemia is given appropriate priority in international and national guidelines. Publications (position papers, literature reviews, etc) R3i scientific sessions at major international congresses R3i press events at major international congresses Collaboration with professional and patients’ groups, as well as policy makers

References